R＆D center
010-61271107Location：Home->R＆D center > Platforms
Molecular immunology department
Molecular immunology department owns everal technology platforms including ELISA/ELISpot, reverse dot blot, and time- resolved fluorescence. The product lines developed can be used for TB infection screening, diagnosis and detection of drug resistance. Among them is the tuberculosis T cell immune detection kit with independent intellectual property (patented in China), which has won CFDA clinical approval and production license; the in- development kit for rapid diagnosis of tuberculosis drug sensitivity based on reverse dot blot will help to achieve an all- round and rapid detection of MDR- TB; the in- development tuberculosis molecular diagnostic kit is simple to use and does not require any special equipment, suitable for the needs of tuberculosis prevention and control at all levels of disease control facilities.
Molecular immunology department has taken part in the major projects of the 12th five- year plan and has established a long- term cooperation with Institute of Microbiology of Chinese Academy of Sciences, Peking University, Tsinghua University, Chinese Center for Disease Control and Prevention and Beijing Chest Hospital. The platform established for the conversion of biological reagents ensures sustained innovation of the product lines.
細胞免疫部
細胞免疫部建立了成熟穩定的流式抗體多色標記平臺以及完善的質控體系，主要開發應用于流式細胞儀的熒光單克隆抗體及配套試劑，以及針對免疫評價、艾滋病診斷、白血病分型和免疫細胞治療等臨床需求而開發的系列診斷產品。目前已開發包括凋亡檢測試劑盒、造血干細胞/間充質干細胞檢測試劑盒、淋巴細胞亞群檢測試劑盒等千余種單克隆抗體產品，其中淋巴細胞亞群檢測試劑盒等部分產品已經獲得國家食品藥品監督管理總局的臨床批文和生產許可，為國內首創，可用于艾滋病的檢測，具有重大的社會意義和經濟價值。
細胞免疫部承擔了國家"十二五"科技重大專項，并與包括協和醫院、301醫院、佑安醫院和中國醫科大學等單位建立了長期合作關系，不斷開發新產品和新應用。
分子診斷部
分子診斷部以microRNA為切入點，專注于重大癌癥、艾滋病、結核病、肝病等microRNA診斷試劑盒的研制，并提供從microRNA表達譜檢測到功能研究的全套技術服務。本平臺采用自主知識產權發明專利"三步法qPCR"技術和獨特的外源RNA對照設計，實現血清、血漿、組織、細胞、石蠟組織切片中microRNA表達量的檢測。
艾滋病快速進展microRNA標志物已申報獲得5項國家發明專利，乳腺癌特異性microRNA標志物已申報獲得4項國家發明專利，乙肝、肝硬化特異性microRNA標志物已申報3項國家發明專利，肝硬化miRNA診斷試劑盒已啟動注冊申報程序。
蛋白免疫部
蛋白免疫部借助于化學發光免疫分析（CLIA）技術平臺，研發出國際首創的K18和K19腫瘤早期篩查輔助診斷試劑盒，及其他11個腫瘤早期篩查輔助診斷系列產品。加上14種甲功、性腺、心肌類臨床輔助診斷產品，全部獲得國家食品藥品監督管理總局的臨床批文和生產許可。其研究結果獲得一項國際專利——用于診斷上皮源性癌癥的血液標志物及其單克隆抗體，一項國內專利——一種紫杉醇緩釋納米粒、制備方法及其應用以及計算機軟件著作權——腫瘤早期篩查風險評估系統。
